新聞稿

 

San Ramon, CA, Nov. 19, 2019 -- BioVentrix, Inc., a privately-held company with a first-in-class, transcatheter-based structural heart device to treat heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation status for its Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure.


San Ramon, CA, USA – Oct. 07, 2019 – BioVentrix, Inc. announced the first patient was enrolled and treated in the REVIVE-HF European study, a prospective multi-center, dual-arm randomized controlled study evaluating the treatment of ischemic cardiomyopathy induced heart failure with the Revivent TC System compared to Guideline-Directed Medical Therapy (GDMT) or drug treatment. 


Image

BioVentrix是一家私營醫療器械公司,總部位於美國加利福尼亞州聖拉蒙。

我們的新聞

聯繫我們

© 2019 BioVentrix。版權所有。由Medtech MomentumMedTech Momentum提供技術支持
Revivent TC™商標是BioVentrix擁有的聯邦註冊商標。明確禁止任何未經授權的使用。